Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of QLC5508 versus docetaxel in metastatic castration-resistant prostate cancer after failure of novel hormonal agents
CTR20262237Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MHB088C in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Radiographic progression-free survival. Started Jul 2026; status: active.
02
Drugs
MHB088C
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20262237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262237.